Skip to main content
PortfolioPoseida Therapeutics, Inc.

Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma

By May 13, 2019March 15th, 2021No Comments